Investigating the Minimum Number of Needling Required to Optimize Trigger Point Injections Outcome
Launched by UNIVERSITY OF ARIZONA · Jan 26, 2021
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Chronic pain affects over 100 million Americans with an annual cost of about $600 billion/year. Almost half of the chronic pain conditions are attributed to musculoskeletal conditions.
Musculoskeletal pain is typically identified with palpation over tender areas initially identified by the patient and then verified by the physician. There are typically areas of muscles that when palpated, pain is experienced by the patient. These points are known as Trigger Points. There are several ways to manage trigger points. Muscle relaxers are the most common pharmacological approaches to manage trig...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Able to speak, read and write English
- • Diagnosis of myofascial pain
- • Failed conservative therapy or unable to participate in physical therapy
- Exclusion Criteria:
- • Serious mental illness that may not enable the patient to perceive pain changes
- • History of conditions which may present as diffuse pain
About University Of Arizona
The University of Arizona is a leading research institution dedicated to advancing healthcare through innovative clinical trials and studies. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources and expertise to explore new therapeutic approaches and enhance patient outcomes. Committed to ethical research practices and community engagement, the University of Arizona fosters an environment that promotes scientific discovery and the translation of research findings into clinical applications. Its clinical trial initiatives encompass a wide range of medical disciplines, reflecting the institution's mission to improve health and well-being locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tucson, Arizona, United States
Patients applied
Trial Officials
Mohab Ibrahim, Md., Ph.D
Principal Investigator
University of Arizona
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials